A lung carcinoma characterized by a combination of small cell carcinoma and squamous cell carcinoma.
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation for lung mixed small cell and squamous cell carcinoma is limited primarily due to its rarity and the complexity of its clinical presentation. As this condition affects a smaller population, systematic clinical studies have been sparse, making it difficult to gather comprehensive data. Additionally, the overlapping features with other lung carcinomas further complicate clinical characterization.
To navigate your care effectively, consider consulting with an oncologist who specializes in lung cancers, particularly those with experience in mixed histology tumors. It is also beneficial to explore participation in clinical trials, which could provide access to cutting-edge therapies. Resources such as the National Organization for Rare Disorders (NORD) at https://rarediseases.org can offer additional support and information. Although there are currently no patient organizations specifically for this condition, connecting with broader lung cancer support networks may provide valuable community resources.
There are currently four active clinical trials investigating treatments for lung mixed small cell and squamous cell carcinoma. Among the orphan drugs designated for this condition, necitumumab is FDA-approved, while others like the anti-CD228 monoclonal antibody conjugated with a monomethyl auristatin payload and gotistobart are in development. For more information on ongoing trials, you can visit https://clinicaltrials.gov/search?cond=lung%20mixed%20small%20cell%20and%20squamous%20cell%20carcinoma.
Actionable guidance for navigating care for lung mixed small cell and squamous cell carcinoma
To navigate your care effectively, consider consulting with an oncologist who specializes in lung cancers, particularly those with experience in mixed histology tumors. It is also beneficial to explore participation in clinical trials, which could provide access to cutting-edge therapies. Resources such as the National Organization for Rare Disorders (NORD) at https://rarediseases.org can offer additional support and information. Although there are currently no patient organizations specifically for this condition, connecting with broader lung cancer support networks may provide valuable community resources.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for lung mixed small cell and squamous cell carcinoma is limited primarily due to its rarity and the complexity of its clinical presentation. As this condition affects a smaller population, systematic clinical studies have been sparse, making it difficult to gather comprehensive data. Additionally, the overlapping features with other lung carcinomas further complicate clinical characterization.
To navigate your care effectively, consider consulting with an oncologist who specializes in lung cancers, particularly those with experience in mixed histology tumors. It is also beneficial to explore participation in clinical trials, which could provide access to cutting-edge therapies. Resources such as the National Organization for Rare Disorders (NORD) at https://rarediseases.org can offer additional support and information. Although there are currently no patient organizations specifically for this condition, connecting with broader lung cancer support networks may provide valuable community resources.
There are currently four active clinical trials investigating treatments for lung mixed small cell and squamous cell carcinoma. Among the orphan drugs designated for this condition, necitumumab is FDA-approved, while others like the anti-CD228 monoclonal antibody conjugated with a monomethyl auristatin payload and gotistobart are in development. For more information on ongoing trials, you can visit https://clinicaltrials.gov/search?cond=lung%20mixed%20small%20cell%20and%20squamous%20cell%20carcinoma.
Actionable guidance for navigating care for lung mixed small cell and squamous cell carcinoma
To navigate your care effectively, consider consulting with an oncologist who specializes in lung cancers, particularly those with experience in mixed histology tumors. It is also beneficial to explore participation in clinical trials, which could provide access to cutting-edge therapies. Resources such as the National Organization for Rare Disorders (NORD) at https://rarediseases.org can offer additional support and information. Although there are currently no patient organizations specifically for this condition, connecting with broader lung cancer support networks may provide valuable community resources.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for lung mixed small cell and squamous cell carcinoma is limited primarily due to its rarity and the complexity of its clinical presentation. As this condition affects a smaller population, systematic clinical studies have been sparse, making it difficult to gather comprehensive data. Additionally, the overlapping features with other lung carcinomas further complicate clinical characterization.
To navigate your care effectively, consider consulting with an oncologist who specializes in lung cancers, particularly those with experience in mixed histology tumors. It is also beneficial to explore participation in clinical trials, which could provide access to cutting-edge therapies. Resources such as the National Organization for Rare Disorders (NORD) at https://rarediseases.org can offer additional support and information. Although there are currently no patient organizations specifically for this condition, connecting with broader lung cancer support networks may provide valuable community resources.
There are currently four active clinical trials investigating treatments for lung mixed small cell and squamous cell carcinoma. Among the orphan drugs designated for this condition, necitumumab is FDA-approved, while others like the anti-CD228 monoclonal antibody conjugated with a monomethyl auristatin payload and gotistobart are in development. For more information on ongoing trials, you can visit https://clinicaltrials.gov/search?cond=lung%20mixed%20small%20cell%20and%20squamous%20cell%20carcinoma.
Actionable guidance for navigating care for lung mixed small cell and squamous cell carcinoma
To navigate your care effectively, consider consulting with an oncologist who specializes in lung cancers, particularly those with experience in mixed histology tumors. It is also beneficial to explore participation in clinical trials, which could provide access to cutting-edge therapies. Resources such as the National Organization for Rare Disorders (NORD) at https://rarediseases.org can offer additional support and information. Although there are currently no patient organizations specifically for this condition, connecting with broader lung cancer support networks may provide valuable community resources.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.